肾功能对β(2)微球蛋白水平作为多发性骨髓瘤国际分期系统预后因素的影响——单中心666例临床分析

OBJECTIVE: To investigate the influence of renal function on the level of β(2)-microglobulin (β(2)-MG) as prognostic factor in newly diagnosed multiple myeloma (MM) patients, and to analyze the overall survival (OS) in different level of β(2)-MG with relatively normal or abnormal renal function in MM patients. METHODS: According to the level of β(2)-MG, 666 newly diagnosed MM patients were divided into three groups as β(2)-MG<3.5, 3.5–<5.5, ≥5.5 mg/L. According to the level of serum creatinine, these patients were divided into two groups: serum creatinine <177 µmol/L as relatively normal group, serum creatinine ≥177 µmol/L as abnormal group. RESULTS: Among 666 patients, there were 416 male and 250 female, the median age was 58 (25–86) years old. Comparison of OS among β(2)-MG<3.5, 3.5–<5.5, ≥5.5 mg/L groups indicated that the median OS of the three groups were 85.75 (95%CI 70.99–100.50), 47.25 (95%CI 40.98–53.53) and 35.05 (95%CI 30.75–39.35) months, respectively (P<0.01). Comparison of OS between serum creatinine <177 and ≥177 mmol/L groups, the median OS of the two groups were 64.67 (95%CI 56.57–72.77) and 32.74 (95%CI 27.74–37.73) months, respectively (P< 0.01). In β(2)-MG≥5.5 mg/L, the median OS of relatively normal and abnormal groups were 37.25 (95%CI 31.45–43.06) and 32.55(95%CI 26.26–38.83) months, respectively (P=0.142). CONCLUSION: High level of β(2)-MG and renal function correlated with shorter survival of MM patients. Higher level of β(2)-MG with abnormal renal function can't change the prognostic value of β(2)-microglobulin on MM.